Codina Ana V, Indelman Paula, Hinrichsen Lucila I, Lamas María C
Instituto de Genética Experimental, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Santa Fe 3100, Rosario S2000KTR, Argentina.
Carrera del Investigador Científico de la Universidad Nacional de Rosario (CIC-UNR), Universidad Nacional de Rosario, Maipú 1065, Rosario S2000CGK, Argentina.
Pharmaceutics. 2025 Aug 19;17(8):1069. doi: 10.3390/pharmaceutics17081069.
This study aimed to analyze whether the enhancement of the biopharmaceutical efficiency of mebendazole, a poorly water-soluble anthelmintic drug, significantly improves its antiparasitic activity in a murine model of trichinellosis. : Two advanced oral formulations were developed, polyvinyl alcohol-derived nanoparticles (NP) and β-cyclodextrin citrate inclusion complexes (Comp), both employing mebendazole as an anthelmintic agent. The primary objective of this work is to treat trichinellosis, an infection with severe chronic effects. : The physicochemical characteristics as well as the in vivo performance of the NP and Comp formulations were assessed. The in vivo studies involved the bioavailability analysis, comparing drug absorption between the pure drug and the novel formulations, as well as the in vitro anthelmintic activity and in vivo therapeutic efficacy against encysted muscle larvae. The in vivo efficacy was evaluated during the parenteral stage of infection in male and female mice from two genetically distinct lines differing in mebendazole pharmacokinetic parameters and susceptibility to the parasite. : The formulations exhibited smaller particle sizes and improved dissolution properties compared to pure MBZ. The pharmacokinetics studies indicate that NP and Comp significantly improved MBZ bioavailability. Both NP and Comp significantly increased mebendazole's anthelmintic activity against the encysted parasites, which would be attributed to the improved MBZ absorption. The formulations overcome the drug's poor solubility and low bioavailability limitations, resulting in a higher plasma concentration of the active drug, even at low doses. : These findings suggest that the newly designed mebendazole formulations are suitable for treating chronic infection and highlight a potential improvement in the pharmacological treatment of trichinellosis.
本研究旨在分析提高难溶性驱虫药甲苯咪唑的生物制药效率是否能显著改善其在旋毛虫病小鼠模型中的抗寄生虫活性。开发了两种先进的口服制剂,聚乙烯醇衍生的纳米颗粒(NP)和β-环糊精柠檬酸盐包合物(Comp),均采用甲苯咪唑作为驱虫剂。这项工作的主要目标是治疗旋毛虫病,一种具有严重慢性影响的感染。评估了NP和Comp制剂的物理化学特性以及体内性能。体内研究包括生物利用度分析,比较纯药物与新制剂之间的药物吸收,以及体外驱虫活性和对包囊化肌幼虫的体内治疗效果。在感染的肠外阶段,对来自两个遗传不同品系、甲苯咪唑药代动力学参数和对寄生虫易感性不同的雄性和雌性小鼠评估体内疗效。与纯甲苯咪唑相比,这些制剂表现出更小的粒径和改善的溶解性能。药代动力学研究表明,NP和Comp显著提高了甲苯咪唑的生物利用度。NP和Comp均显著提高了甲苯咪唑对包囊化寄生虫的驱虫活性,这归因于甲苯咪唑吸收的改善。这些制剂克服了药物溶解度差和生物利用度低的局限性,即使在低剂量下也能使活性药物的血浆浓度更高。这些发现表明,新设计的甲苯咪唑制剂适用于治疗慢性感染,并突出了旋毛虫病药物治疗的潜在改善。